{"id":27021,"date":"2023-06-22T12:12:38","date_gmt":"2023-06-22T16:12:38","guid":{"rendered":"https:\/\/capital10x.com\/old\/?p=27021"},"modified":"2023-06-22T12:14:16","modified_gmt":"2023-06-22T16:14:16","slug":"mindset-pharma-phase-ii-clinical-trial-mdd","status":"publish","type":"post","link":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/","title":{"rendered":"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder"},"content":{"rendered":"

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF)<\/strong> announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the “MHRA”) and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).<\/p>\n

Our team has worked diligently and tirelessly to achieve this major regulatory milestone. With today’s announcement, MSP-1014 now has a clear path to become one of the most clinically advanced psilocin-based novel chemical entity (NCE). As psilocybin continues to make strides in its ongoing clinical development, the opportunity for novel optimized drug candidates is expanding significantly. Moreover, this announcement demonstrates that Mindset is delivering on its commitment to making the leap to becoming a clinical stage biotech company focused on novel and patentable psychedelic-inspired therapeutics. James Lanthier, CEO, Mindset Pharma<\/span><\/div><\/div>\n

About the MSP-1014 Phase II Trial<\/h2>\n

The Phase II study will be conducted in two parts. In Part 1, Mindset will assess the safety and tolerability of up to three escalating doses of MSP-1014. In conjunction with MSP-1014, study participants will receive Acceptance and Commitment Therapy (ACT).<\/p>\n

In Part 2, a randomized and placebo-controlled study, Mindset will assess the safety and efficacy of a single dose of MSP-1014, selected from Part 1. An equal number of patients will receive MSP-1014 or placebo (non-active) control and all will receive 6 sessions of ACT.<\/p>\n

This is an exciting milestone as we prepare to enter our first-in-human clinical trial with our novel psilocin prodrug, MSP-1014. Based on pre-clinical data, we believe that MSP-1014 has the potential to be a better tolerated psychedelic therapeutic compared to psilocybin. This approval for a Phase II study should provide us with a strong efficacy signal and expedite our pathway to approval for MSP-1014 as a new effective and more tolerable treatment for patients suffering from MDD. Joseph Araujo, CSO, Mindset Pharma<\/span><\/div><\/div>\n

MSP-1014<\/h2>\n

MSP-1014 is a novel and patent-protected prodrug of psilocin, the active metabolite of psilocybin. MSP-1014 is anticipated to exert similar efficacy to psilocybin in improving symptoms of depression. Preclinical studies comparing MSP-1014 to psilocybin suggest that the tolerability of MSP-1014 may be superior to psilocybin.<\/p>\n

MSP-1014, which sits outside of Mindset’s collaboration with the McQuade Center for Strategic Research and Development, is derived from Mindset’s “Family 1” of novel drugs, which enjoys robust composition of matter intellectual property protection in multiple jurisdictions. The Phase II clinical trial may commence as early as Q4 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the “MHRA”) and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).<\/p>\n","protected":false},"author":25,"featured_media":24063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[56,59],"tags":[2202,2109,2025,2287,2203,1825,1824],"class_list":{"0":"post-27021","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-featured","8":"category-metals","9":"tag-cse-mset","10":"tag-investing-in-psychedelics","11":"tag-major-depressive-disorder","12":"tag-mindset-pharma-inc","13":"tag-otcqb-msstf","14":"tag-psilocybin","15":"tag-psychedelics"},"acf":[],"yoast_head":"\nMindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder | Capital 10X<\/title>\n<meta name=\"description\" content=\"Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the "MHRA") and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder | Capital 10X\" \/>\n<meta property=\"og:description\" content=\"Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the "MHRA") and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/\" \/>\n<meta property=\"og:site_name\" content=\"Capital 10X\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Capital10x\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-22T16:12:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-22T16:14:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1069\" \/>\n\t<meta property=\"og:image:height\" content=\"713\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Duane Hope\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@capital10x\" \/>\n<meta name=\"twitter:site\" content=\"@capital10x\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Duane Hope\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/\"},\"author\":{\"name\":\"Duane Hope\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\"},\"headline\":\"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder\",\"datePublished\":\"2023-06-22T16:12:38+00:00\",\"dateModified\":\"2023-06-22T16:14:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg\",\"keywords\":[\"CSE: MSET\",\"investing in psychedelics\",\"major depressive disorder\",\"Mindset Pharma Inc.\",\"OTCQB: MSSTF\",\"Psilocybin\",\"Psychedelics\"],\"articleSection\":[\"Featured\",\"Metals\"],\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/\",\"url\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/\",\"name\":\"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder | Capital 10X\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg\",\"datePublished\":\"2023-06-22T16:12:38+00:00\",\"dateModified\":\"2023-06-22T16:14:16+00:00\",\"description\":\"Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the \\\"MHRA\\\") and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).\",\"breadcrumb\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg\",\"width\":1069,\"height\":713},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/capital10x.com\/old\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Featured\",\"item\":\"https:\/\/capital10x.com\/old\/featured\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/capital10x.com\/old\/#website\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"name\":\"Capital 10X\",\"description\":\"Identifying 10X Investment Opportunities\",\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/capital10x.com\/old\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/capital10x.com\/old\/#organization\",\"name\":\"Capital 10X\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"width\":128,\"height\":90,\"caption\":\"Capital 10X\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Capital10x\/\",\"https:\/\/x.com\/capital10x\",\"https:\/\/www.instagram.com\/capital10x\",\"https:\/\/www.linkedin.com\/company\/capital10x\/\",\"https:\/\/www.pinterest.com\/capital10x\",\"https:\/\/www.youtube.com\/Capital10X\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\",\"name\":\"Duane Hope\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"caption\":\"Duane Hope\"},\"description\":\"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.\",\"sameAs\":[\"http:\/\/capital10x.com\"],\"url\":\"https:\/\/capital10x.com\/old\/author\/duanehope\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder | Capital 10X","description":"Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the \"MHRA\") and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/","og_locale":"en_US","og_type":"article","og_title":"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder | Capital 10X","og_description":"Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the \"MHRA\") and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).","og_url":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/","og_site_name":"Capital 10X","article_publisher":"https:\/\/www.facebook.com\/Capital10x\/","article_published_time":"2023-06-22T16:12:38+00:00","article_modified_time":"2023-06-22T16:14:16+00:00","og_image":[{"width":1069,"height":713,"url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg","type":"image\/jpeg"}],"author":"Duane Hope","twitter_card":"summary_large_image","twitter_creator":"@capital10x","twitter_site":"@capital10x","twitter_misc":{"Written by":"Duane Hope","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#article","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/"},"author":{"name":"Duane Hope","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851"},"headline":"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder","datePublished":"2023-06-22T16:12:38+00:00","dateModified":"2023-06-22T16:14:16+00:00","mainEntityOfPage":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"image":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg","keywords":["CSE: MSET","investing in psychedelics","major depressive disorder","Mindset Pharma Inc.","OTCQB: MSSTF","Psilocybin","Psychedelics"],"articleSection":["Featured","Metals"],"inLanguage":"en-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/capital10x.com\/old\/#organization"}},{"@type":"WebPage","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/","url":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/","name":"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder | Capital 10X","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/#website"},"primaryImageOfPage":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage"},"image":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg","datePublished":"2023-06-22T16:12:38+00:00","dateModified":"2023-06-22T16:14:16+00:00","description":"Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the \"MHRA\") and the Research Ethics Committee to initiate a Phase II study of MSP-1014, its novel psilocin prodrug, evaluating its safety and efficacy in treating patients suffering from major depressive disorder (MDD).","breadcrumb":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/"]}]},{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#primaryimage","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-09.jpg","width":1069,"height":713},{"@type":"BreadcrumbList","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-phase-ii-clinical-trial-mdd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/capital10x.com\/old\/"},{"@type":"ListItem","position":2,"name":"Featured","item":"https:\/\/capital10x.com\/old\/featured\/"},{"@type":"ListItem","position":3,"name":"Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder"}]},{"@type":"WebSite","@id":"https:\/\/capital10x.com\/old\/#website","url":"https:\/\/capital10x.com\/old\/","name":"Capital 10X","description":"Identifying 10X Investment Opportunities","publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/capital10x.com\/old\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/capital10x.com\/old\/#organization","name":"Capital 10X","url":"https:\/\/capital10x.com\/old\/","logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","width":128,"height":90,"caption":"Capital 10X"},"image":{"@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Capital10x\/","https:\/\/x.com\/capital10x","https:\/\/www.instagram.com\/capital10x","https:\/\/www.linkedin.com\/company\/capital10x\/","https:\/\/www.pinterest.com\/capital10x","https:\/\/www.youtube.com\/Capital10X\/"]},{"@type":"Person","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851","name":"Duane Hope","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","caption":"Duane Hope"},"description":"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.","sameAs":["http:\/\/capital10x.com"],"url":"https:\/\/capital10x.com\/old\/author\/duanehope\/"}]}},"_links":{"self":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/27021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/comments?post=27021"}],"version-history":[{"count":2,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/27021\/revisions"}],"predecessor-version":[{"id":27023,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/27021\/revisions\/27023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media\/24063"}],"wp:attachment":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media?parent=27021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/categories?post=27021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/tags?post=27021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}